

First-phase release and model of pore space network in a sustained release system


Xutao Shi

Student Presenter for Rigaku X-ray Computed Tomography Seminar

Biopharmaceutical & drug delivery systems

Small molecule


Aspirin
(180 Da)



~ 0.5 nm

Biopharmaceutical

Pembrolizumab (*antibody*)
(150,000 Da)




~ 15 nm

Biopharmaceutical & drug delivery systems


Advantages:

- Protection against drug degradation/denaturation
- High specificity
- Less frequent administration
- Long-term bioavailability
- Improved patient compliances



Motivation & research question

- Release process is dictated by complex interactions between delivery systems and environment
- Tight control of the release profile is a major challenge in the design of delivery systems
- A physically-based model can enable prediction outside experimentally verified behavior




Drug-loaded polymer matrix
Drug release

Research question:

How well can we understand/inform the design of drug delivery system using a physically-based model?

Release process of poly(lactic-co-glycolic acid)-based (PLGA) delivery systems



Experimental design


Parameter space

- 5 design factors (level varied around A)
- Mostly one factor at a time approach

Parameter space (partial)

Design Parameter	Formula A	Formula D	Formula E	Formula F	Formula I
Polymer initial MW [kDa]	60	110	60	60	60
Drug loading [wt%]	15	15	5	25	15
L:G ratio	75:25	75:25	75:25	75:25	85:15
Polymer grade & end-group*	5S	6S	5S	5S	5A

*Number: Intrinsic viscosity/MW; S: ester; A: acid



Problem Statement



Implantable polymer rods that release bio-agents via physic-chemical processes

Processes:

- Drug diffusion out
- Water diffusion in
- Matrix degradation

Degradative reaction


- PLGA hydrolysis



Methods – modeling approach


Modeled uptake and release mechanisms:

- Drug:
$$\frac{\partial C_D}{\partial t} = \frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial}{\partial r} D_D(r, t) C_D \right)$$
- Water:
$$\frac{\partial C_W}{\partial t} = \frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial}{\partial r} D_W C_W \right) - k[E] C_W$$
- Polymer:
$$\frac{\partial C_E}{\partial t} = -k C_E C_W \quad C_E = \rho \left(\frac{1}{M_0} - \frac{1}{MW} \right)$$



Model Parameter	Variable	Method
Drug diffusion coefficient	$D_{D,0}$	Heuristic
Drug initial concentration	$C_{D,0}$	Design
Water diffusion coefficient	D_W	Estimation
Water maximum concentration	$C_{w,0}$	Estimation
Occlusion radius	R_{occ}	Heuristic
Radius of cylinder	R	Design
Initial polymer MW	MW_0	Design
Polymer MW at release	MW_r	Estimation
Polymer degradation rate constant	k_{deg}	Fit
Polymer degradation variance	σ_r^2	Estimation

Previous rate law
$$\frac{\partial MW}{\partial t} = -kMW C_w$$



Methods – modeling approach

Modeled uptake and release mechanisms:

- Drug: $\frac{\partial C_D}{\partial t} = \frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial}{\partial r} D_D(r, t) C_D \right)$
- Water: $\frac{\partial C_W}{\partial t} = \frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial}{\partial r} D_W C_W \right) - k[E] C_W$
- Polymer: $\frac{\partial C_E}{\partial t} = -k C_E C_W$ $C_E = \rho \left(\frac{1}{M_0} - \frac{1}{MW} \right)$

Model Parameter	Variable	Method
Drug diffusion coefficient	$D_{D,0}$	Heuristic
Drug initial concentration	$C_{D,0}$	Design
Water diffusion coefficient	D_W	Estimation
Water maximum concentration	$C_{W,0}$	Estimation
Occlusion radius	R_{occ}	Heuristic
Radius of cylinder	R	Design
Initial polymer MW	MW_0	Design
Polymer MW at release	MW_r	Estimation
Polymer degradation rate constant	k_{deg}	Fit
Polymer degradation variance	σ_r^2	Estimation


Position-dependent

$$D_D(r, t) = \begin{cases} D_{D,0}; & \text{if } r > (R - R_{occ}) \\ D_{D,0} \cdot \epsilon(MW(r, t)); & \text{if } r \leq (R - R_{occ}) \end{cases}$$

MW-dependent

$$\epsilon(MW(r, t)) = 1 - \frac{1}{2} \left[1 + \operatorname{erf} \left(\frac{MW(r, t) - MW_r}{\sqrt{2\sigma_r^2}} \right) \right]$$

Cylindrical 1D domain



First-phase release



Hypothesis to be investigated:

- Percolation of drug particles within the polymer rods (threshold ~ 0.2 ; spheres; jammed)
- Faster water penetration and pore formation

Supporting evidence:

- CFM images of FITC-dextran particles
- Apparent particle volume percent from binary transformation

CFM image of formulation A (Inset is binary transformation)



First-phase release

Hypothesis to be investigated:

- Percolation of drug particles within the polymer rods (threshold ~ 0.2 ; spheres; jammed)
- Faster water penetration and pore formation

Supporting evidence:



- CFM images of FITC-dextran particles
- Apparent particle volume percent from binary transformation

CFM images supporting pore formation



Day 0

Week 7



5% drug load



15% drug load




25% drug load




Limitations of CFM

Hypothesis to be investigated:

- Percolation of drug particles within the polymer rods (threshold ~ 0.2 ; spheres; jammed)
- Faster water penetration and pore formation



Microscopy - CFM results



CFM disadvantages:



1. *Only recognize discrete FITC distr.*
2. *Very destructive*
→ *Evolution is unavailable*
3. *Restricted to 2D*
→ *Network analysis is limited*





X-ray CT Nano3Dx

Advantages:

1. Contrast based on density
2. Non-destructive loading
3. Optical resolution $0.325 \mu\text{m}/\text{px}$
4. 3D reconstruction
5. Image segmentation (*Dragonfly*)




Pore Space Network




Dextran particle size ~ 5 μm



Pore Space Network




Cross-section




3D reconstruction



Pore Space Characterization



Pore Space Characterization



Pore dynamics:

Spherical

Growing

Merging

Population Balance

Pore Space Characterization

Population balance – moment method

$$\frac{dv_j}{dt} = \dot{B}V_0^j + jG_0v_{j-1/3} + \beta_0 \left[\sum_{k=0}^j \binom{j}{k} (v_k v_{j-k} + v_{k+1/3} v_{j-k-1/3}) - v_{1/3+j} v_{-1/3} - v_{1/3} v_{j-1/3} - 2v_0 v_j \right]$$

Special moments:

- Number balance:

$$\frac{\partial v_0}{\partial t} = \dot{B} - \beta_0 [-v_0 v_0 - v_{1/3} v_{-1/3}]$$

- Mass balance:

$$\frac{\partial v_1}{\partial t} = \dot{B}V_0 + G_0 v_{2/3}$$

- Variance balance:


$$\frac{\partial v_2}{\partial t} = \dot{B}V_0^2 + 2G_0 v_{5/3} + 2\beta_0 [v_1 v_1 + v_{4/3} v_{2/3}]$$

Non-integer moment closure by distribution/MOMIC




Pore Space Characterization


F2D Total Volume Distribution (40 bins)



Volume Survival Function



Pore Space Characterization



Pore Space Characterization



Pore domain utility:

1. Refit beta distribution using PBM-predicted moments
2. Reconstruct porous domains in evolution
3. Implement Little/Antheunis model with moving pore mesh

$$\begin{bmatrix} \mu_1 \\ \mu_2 \\ \mu_3 \end{bmatrix}$$

1

2



3

2D Transport/kinetics model*


- Drug: $\xi_0 \frac{\partial}{\partial \tau} y_1 - \frac{\partial}{\partial \eta_1} \left[\xi \frac{\partial}{\partial \eta_1} y_1 \right] - \frac{\partial}{\partial \eta_2} \left[\xi \frac{\partial}{\partial \eta_2} y_1 \right] = 0$
- Water: $\xi_0 \frac{\partial}{\partial \tau} y_2 - \frac{\partial}{\partial \eta_1} \left[\frac{\partial}{\partial \eta_1} y_2 \right] - \frac{\partial}{\partial \eta_2} \left[\frac{\partial}{\partial \eta_2} y_2 \right] + D_a y_2 y_3 = 0$
- MW: $\xi_0 \frac{\partial}{\partial \tau} y_3 + \varphi D_a y_2 y_3 = 0$
- $y_3 = \frac{\rho_R}{[E]_0} \left(\frac{1}{MW_0} - \frac{1}{MW} \right)$





Conclusion & Recap.

- Mechanistic model & First-phase release
- Hypothesis: Percolation in pores
- XRCT: confirm early-stage pore formation
- Evolution of pore space distribution
- Population balance model

F2D 3D Reconstr.





Acknowledgements




Modified model prediction

Design Parameter	Formula A	Formula F
Polymer initial MW [kDa]	60	60
Drug loading [wt%]	15	25
L:G ratio	75:25	75:25
End-group	S	S



With fitted occlusion radius:

- Close fit in MW profiles
- Capturing first-phase release
- Occlusion radius spans differently based on extent of burst release



High drug load

&


High L:G

Experimental observations:

- Formulation A and F show significant first-phase release
- Reference does not reach complete release
- Higher L:G ratio (I) alone does not lead to slow degradation, indicating strong influence by the acid end-group.
- Water uptake occurs quickly and remains constant

Design Parameter	Formula A
Polymer initial MW [kDa]	60
Drug loading [wt%]	15
L:G ratio	75:25
End-group	S

Formula F	Formula I
60	60
25	15
75:25	85:15
S	A



High drug load

&


High L:G

Experimental observations:

- Formulation A and F show significant first-phase release
- Reference does not reach complete release
- Higher L:G ratio (I) alone does not lead to slow degradation, indicating strong influence of the acid end-group
- Water uptake occurs quickly and remains constant

Design Parameter	Formula A
Polymer initial MW [kDa]	60
Drug loading [wt%]	15
L:G ratio	75:25
End-group	S

Formula F	Formula I
60	60
25	15
75:25	85:15
S	A



High drug load

&


High L:G

Design Parameter	Formula A
Polymer initial MW [kDa]	60
Drug loading [wt%]	15
L:G ratio	75:25
End-group	S

Formula F	Formula I
60	60
25	15
75:25	85:15
S	A

Model predictions (initial):


- Sigmoidal drug release profile
- Higher drug loading only affects the absolute amount of release (not the relative shape)
- Does not capture first-phase release
- Discrepancy in drug release from MW profiles



First-phase release

Supporting evidence:

- CFM images of FITC-dextran particles
- Apparent particle volume percent from binary transformation
- Pore formation motivates occlusion radius fitting



*Not drawn to scale

CFM images supporting pore formation







5% drug load

15% drug load

25% drug load

Day 0

Week 7



Low drug load


&

High MW

Experimental observations:

- Formulations A and D show significant first-phase release
- All 3 formulations show incomplete release
- Similar rate of polymer degradation, indicating un-affected hydrolysis at higher polymer MW and lower drug loading

Design Parameter	Formula A	Formula D	Formula E
Polymer initial MW [kDa]	60	110	60
Drug loading [wt%]	15	15	5
L:G ratio	75:25	75:25	75:25
End-group	S	S	S



Low drug load


&

High MW


Design Parameter	Formula A	Formula D	Formula E
Polymer initial MW [kDa]	60	110	60
Drug loading [wt%]	15	15	5
L:G ratio	75:25	75:25	75:25
End-group	S	S	S

Model predictions (initial):

- Sigmoidal drug release profile
- Higher polymer molar mass/lower drug loading does not affect predicted rate of degradation
- Does not capture first-phase release
- Discrepancy in drug release from MW profiles




Methods – release characterization




First-phase release

Preliminary explanations:

- Rapid erosion due to polymer $\sigma_{MW} \gg MW_0$



- Occlusion radius ($\sim 2\%$ of rod radius)



*Not drawn to scale




Limitations/Hypothesis

Features:


- Burst release
- Incomplete release
- End-phase degradation lag

Hypothesis

Early pore formation



Potential drug dumping




Limitations/Hypothesis

Hypothesis

Early pore formation

Preliminary Evidence



Formula F

